Glofitamab,Atezolizumab,Polatuzumab Vedotin,Obinutuzumab,Tocilizumab,89Zr-Df-IAB22M2C
Roche,Imaginab,JW Pharma
['pola', 'dlbcl', 'polatuzumab', 'congrat', 'glofitamab']
#17icml glofitamab + polatuzumab presented early today, promising combination for r/r dlbcl, short follow up, but good rates of response, acceptable aes profile, we should be following this combination! congrats dr hutchings 
Hematology